Startseite
Kongressberichte & Archiv
ASCO20 Virtual Scientific Meeting
Oral Sessions
Gastrointestinal Cancer II
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
4500 Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010.
The abstract concludes:
The addition of tras/per to perioperative FLOT significantly improved pCR and nodal negativity rates in pts with Her2+ resectable esophagogastric adenocarcinoma at the price of higher rates of diarrhea and leukopenia. Clinical trial information: NCT02581462.
————————————————————————————————————————————————————————————————————————————
This long-term analysis found that second-line pembrolizumab prolonged OS among patients with PD-L1–positive GC and led to fewer drug-related AEs vs paclitaxel. Clinical trial information: NCT02370498.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
We have demonstrated: 1) two-year OS of 41.6% (median 22.4 months) with mFOLFIRINOX and 48.8% (median 23.6 months) with Gem/nabP for all eligible pts starting treatment for resectable PDA; 2) post-resection DFS of 10.9 months and 14.2 months, respectively; 3) adequate safety and high resectability rates with peri-op CTx; 4) little evidence that either regimen improves OS compared with the historical standard. Clinical trial information: NCT02562716.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
There was no difference in resection rate between arms, however neoadjuvant therapy had a significant survival benefit compared with immediate surgery. Clinical trial information: 89500674.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
Donafenib significantly improves OS over sorafenib with favourable safety and tolerability. Donafenib is a promising superior first-line therapy for advanced HCC. Funding: Zelgen. Clinical trial information: NCT02645981.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
————————————————————————————————————————————————————————————————————————————
————————————————————————————————————————————————————————————————————————————
4532 Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.
Ramon Jin, Haeseong Park, Andrea Wang-Gillam, et al.
The abstract concludes:
FOLFIRINOX is a highly effective three-drug regimen for first-line treatment of advanced gastroesophageal cancer with expected, tolerable toxicities. Clinical trial information: NCT01928290.
Published simultaneously in JAMA Oncology:
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial
Haeseong Park, MD; Ramon U. Jin, MD; Andrea Wang-Gillam, MD; et al.
————————————————————————————————————————————————————————————————————————————
Zev A. Wainberg, Tanios S. Bekaii-Saab, Richard Hubner, et al.
- The primary endpoint is overall survival (OS).
- Secondary endpoints (progression-free survival [PFS] and overall response rate assessed with Response Evaluation Criteria in Solid Tumors v1.1 criteria) will be compared only if the primary endpoint shows superiority for liposomal irinotecan + 5-FU/ LV + OX over nab-paclitaxel + gemcitabine.
Clinical trial information: NCT04083235
————————————————————————————————————————————————————————————————————————————
4624 Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).
Hongjae Chon, Hyung Soon Park, Beodeul Kang, et al.
The abstract concludes:
In second-line setting for mPC after progression on gemcitabine-based therapy, both nal-IRI/FL and FOLFIRINOX regimen showed comparable efficacy and acceptable safety outcomes. FOLFIRINOX regimen might be preferentially considered in patients with liver metastasis.
————————————————————————————————————————————————————————————————————————————
Esther Pijnappel, Judith de Vos-Geelen, Teresa Macarulla Mercade, et al.
- multi-center, open label, randomized phase II trial. Patients ≥ 18 years of age with histologically or cytologically confirmed PDAC, previously treated with gemcitabine (-based) therapy, or progression within 6 months of adjuvant gemcitabine-based treatment are eligible. After a safety run-in of the nal-IRI plus S-1 regimen, patients will be randomized between nal-IRI plus S-1 and nal-IRI plus 5-FU/LV.
Clinical trial information: NCT03986294.
————————————————————————————————————————————————————————————————————————————
Andrew Eugene Hendifar, Sungjin Kim, Mourad Tighiouart, et al.
The abstract concludes:
Bermekimab, nano-liposomal irinotecan and 5-fluorouracil in refractory pancreatic cancer patients with cachexia was well-tolerated with promising efficacy and improvements in patient performance. Clinical trial information: NCT03207724.
————————————————————————————————————————————————————————————————————————————
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
The abstract concludes:
T-DXd demonstrated statistically significant and clinically meaningful improvements in ORR and OS compared with standard chemotherapy (paclitaxel or irinotecan) in patients with HER2+ advanced gastric or GEJ adenocarcinoma. Clinical trial information: NCT03329690.
Published simultaneously in the NEJM:
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
K. Shitara and Others
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:view slide set
————————————————————————————————————————————————————————————————————————————
MORE ABSTRACTS:
Poster Discussion Session
Poster Session
|